Skip to main content

Advertisement

Table 3 Safety parameters

From: Selective peroxisome proliferator-activated receptorα modulators (SPPARMα): The next generation of peroxisome proliferator-activated receptor α-agonists

Compound Aleglitazar GFT505 K-877 Fenofibrate
Study SYNCHRONY[43, 44] S1[48] S2[48] K-877 P2[50] FIELD[12] K-877[50]
Dosage 150 μ g QD 80 mg QD 80 mg QD 100 μ g BID 200 mg QD 100 mg QD
Time point (weeks) 16 4 4 12 16 12
ALT (UI/L) NA −7.1 −2.1 −7.6 NA −4.2
γGT (UI/L) NA −11.0 −6.0 −24.6 NA 0.0
Serum creatinine (mg/dL) NA 0.038* 0.057* 0.013 NA 0.086
Homocysteine (nmol/mL) NA 1.71 −0.8 0.16 NA 2.21
  1. ALT alanine aminotransferase; BID twice-daily; γGT γ-glutamyl transpeptidase; NA not available; QD once daily.
  2. Data are expressed as mean changes from baseline.
  3. *To convert from μmol/L to mg/dL, values were divided by 88.4.